Inhibikase Therapeutics (IKT) EBIT Growth (1y) (2021 - 2026)
Powered by 
Analysis
Inhibikase Therapeutics (IKT) EBIT Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 8.32% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 19.82% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 145.20% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 10.14% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 269.85% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1,528.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -36.55% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 99.51% |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - | -94.34% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -94.34% |
| Mar 31, 2026 | -22.22% |
| Dec 31, 2025 | -6.55% |
| Sep 30, 2025 | -119.11% |
| Jun 30, 2025 | -114.48% |
| Mar 31, 2025 | -205.25% |
| Dec 31, 2024 | -193.60% |
| Sep 30, 2024 | -22.20% |
| Jun 30, 2024 | 18.57% |
| Mar 31, 2024 | -1.43% |
| Dec 31, 2023 | -1.58% |
| Sep 30, 2023 | -5.67% |
| Jun 30, 2023 | -33.67% |
| Mar 31, 2023 | -1.60% |
| Dec 31, 2022 | 14.01% |
| Sep 30, 2022 | -0.94% |
| Jun 30, 2022 | -76.53% |
| Mar 31, 2022 | -76.77% |
| Dec 31, 2021 | -319.83% |
| Sep 30, 2021 | -573.64% |